Plain-English translation of NCT06696235 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing the best timing for starting continuous renal replacement therapy (CRRT)—a type of kidney-filtering treatment—in patients with severe heart failure who are on extracorporeal membrane oxygenation (ECMO), a heart-lung support machine. Half of the patients will start this treatment right away, while the other half will wait until their kidney problems become more serious. The goal is to see which approach helps patients survive better and recover more fully.
When the heart fails severely, patients need life support, but this can put extra stress on the kidneys and cause fluid to build up dangerously in the lungs. Doctors believe removing excess fluid early with kidney-filtering treatment might prevent further organ damage and improve survival, but no large study has proven the best time to start this treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will start kidney-filtering treatment within 6 hours of being placed on life support. The other group will wait and only start the treatment if specific warning signs appear in your blood work or urine output. Throughout your hospital stay, the medical team will closely monitor your kidney function, blood chemistry, and overall condition. You will continue to receive all the standard care for your heart failure and will be followed until you either go home or until 90 days in the hospital, whichever comes first.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
South Korea